Navigation Links
Benefits outweigh risks associated with newborn screening for disorder
Date:2/1/2010

Newborn screening for a metabolic disorder could lead to false positives -- adding stress to parents, costing money and possibly subjecting a baby to unnecessary follow-up treatment and dietary restrictions.

But the benefits of diagnosing these children early and preventing the risk of mental retardation, disability or death outweigh the costs of a false positive, according to new U-M research published today in the February issue of the journal Pediatrics.

"Published studies of expanded newborn screening in a U.S. setting have resulted in favorable cost-effective ratios for screening for this illness but did not include primary data for quality of life effects for a false positive screen," says Lisa Prosser, Ph.D., Research Associate Professor in the Division of General Pediatrics at the University of Michigan Health System and the study's lead author. "Our results show that newborn screening remains cost-effective after accounting for the measured loss in quality of life associated with a false positive screen."

The metabolic disorder commonly referred to as MCADD or medium chain acyl-CoA dehydrogenase deficiency -- shows up in one of 15,000 newborns.

When the MCAD enzyme is not working or missing, the body cannot use certain types of fat for energy. This can lead to low blood sugar, or hypoglycemia, and the build-up of harmful substances in the blood. While MCADD patients are usually healthy, repeated episodes of metabolic crisis can cause permanent brain damage. This may result in learning problems and mental retardation.

Researchers used a computer model that took into account costs of screening, including the initial screen test, parent time and medical costs of follow-up testing, treatment and the quality of life implications of having dietary restrictions.

They found that screening requires substantial investment of resources but in exchange for important health benefits. The costs of newborn screening for the illness amounted to $21,000 for every quality-adjusted life year that was gained. A quality-adjusted life year can be thought of as representing a year in perfect health.

"The cost-effectiveness of newborn screening for MCADD is comparable to cost-effectiveness for other childhood interventions, such as vaccinations," Prosser says.

As the number of screened conditions increases, the number of false positives and associated costs also increase, along with the possible identification and treatment of children who may not have experienced related medical problems in the absence of screening, she adds.

"Newborn screening for MCADD remains cost-effective even when the loss in quality of life associated with false positives or dietary treatments are taken into account," Prosser concludes.


'/>"/>

Contact: Margarita Bauza-Wagerson
mbauza@umich.edu
734-764-2220
University of Michigan Health System
Source:Eurekalert

Related medicine news :

1. Original Sewing & Quilt Expo Boosts Benefits
2. State Teachers Retirement System of Ohio Goes Live on V3 Benefits Administration System
3. Machinists Union Leaders Vote to Oppose Health Benefits Tax
4. Quitline messages that stress benefits of quitting may improve smoking cessation
5. The Pill Offers Benefits Beyond Birth Control
6. The Garlands of Barrington Earns International Recognition, Residents Reap the Benefits of Award-Winning EngAGE Lifestyle
7. Jersey Boys' Premiere Benefits Cancer Patients While Launching Beaumont Hospitals Fundraising Campaign
8. Hallmark Insights' Employer Survey Reveals Cost-Savings Benefits of Health & Wellness Programs
9. Physicians Health Choice Receives Senior Choice Gold Award for 2010 Medicare Plan Benefits
10. University of Utah Announces New Studies on the Benefits of Treadmill Desks
11. New National Study Spotlights Importance of Federal Medicare Funding to Propping-Up Seniors Deteriorating State Medicaid Benefits and Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2017)... Tampa, Fla. (PRWEB) , ... June 24, 2017 ... ... Fla., is now offering genetic testing for medications in select Florida and Texas ... of pharmacogenomics. , This new application of genetic testing recognizes the role ...
(Date:6/23/2017)... ... June 23, 2017 , ... The Rhode Island ... Care Management Alerts and Dashboards, an innovative new service enabling healthcare providers to ... Care Management Alerts and Dashboards provide near real-time data about patients admitted to ...
(Date:6/23/2017)... ... June 23, 2017 , ... The Military Officers Association of America (MOAA) announced ... Veterans Affairs, retired Marine Col. Thomas G. Bowman. , Bowman currently serves as the ... an intimacy with the issues and challenges veterans face with the VA. Following a ...
(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... The Aesthetic ... facelift . Dr. Talei has come up with a proprietary technique that he calls ... lifts tissues that have dropped. For all ages, patients can expect to look refreshed, ...
(Date:6/23/2017)... Santa Monica, CA (PRWEB) , ... June 23, 2017 , ... ... PureLife as the endorsed amalgam separator supplier for CDA members. As part of the ... a reduced price of $99, saving more than $400 off the retail value. This ...
Breaking Medicine News(10 mins):
(Date:6/9/2017)... ALTO, Calif. , June 9, 2017 ... device company focused on the design, manufacture, sale and ... the market on the progress of its commercial roll-out ... is now available in more than one hundred (100) ... AeroForm offers a needle-free alternative for ...
(Date:6/7/2017)... , June 7, 2017 Endo International ... June 7, 2017, the Hon. Joseph R. Goodwin ... of West Virginia , entered a ... Inc. Pelvic Repair System Products Liability Litigation (the "MDL") ... MDL cases to provide expert disclosures on specific causation ...
(Date:6/3/2017)... -- Eli Lilly and Company (NYSE: LLY ... 3 MONARCH 2 study showed that abemaciclib, a ... with fulvestrant, significantly improved progression-free survival (PFS) compared ... hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative ... progressed after endocrine therapy (median PFS, 16.4 vs. ...
Breaking Medicine Technology: